- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05457855
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone
July 25, 2025 updated by: Rishi J. Desai, Brigham and Women's Hospital
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Study Overview
Detailed Description
This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital.
DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program.
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.
Study Type
Observational
Enrollment (Actual)
51533
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
This study will employ a new user, active comparator, observational cohort study design comparing Montelukast versus Fluticasone.
The patients will be required to have continuous enrollment during the baseline period of 365 days before initiation of study drugs (cohort entry/index date).
Follow-up for the outcome (dementia) differs between analyses.
Follow-up begins the day after drug initiation (analysis 1, 3, 4); 180 days after drug initiation (analysis 2).
Description
Please see https://docs.google.com/spreadsheets/d/1u8YFpnMHI5HprhyuY14tIgd1COZcsAWKFlbYCT7aL_A/edit?usp=sharing or Appendix A (https://drive.google.com/file/d/1uC_G8TJ1ujoJbas1p1gFaYFzY7Hw7xMq/view?usp=sharing) for full code and algorithm definitions.
Medicare timeframe: 2008 to 2018 (end of data availability).
Inclusion Criteria:
- 1. Aged >/= 65 years on the index date
- 2. No prior use of Montelukast and Fluticasone anytime prior to cohort entry date
- 3. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
- 4. At least two claims with asthma diagnosis measured 365 days prior to drug init
Exclusion Criteria:
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. Prior history of nursing home admission in the 365 days prior to the cohort entry date
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Montelukast
Exposure group
|
Montelukast claim is used as the exposure group.
|
|
Fluticasone
Reference group
|
Fluticasone claim is used as the reference group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Dementia Onset
Time Frame: Median follow up times: 1) 161 days (exp), 120 days (ref) 2) 504 days (exp), 638 days (ref) 3) 212 days (exp), 130 days (ref) 4) 162 days (exp), 120 days (ref)
|
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere.
Please refer to uploaded protocol for full definition due to size limitations.
|
Median follow up times: 1) 161 days (exp), 120 days (ref) 2) 504 days (exp), 638 days (ref) 3) 212 days (exp), 130 days (ref) 4) 162 days (exp), 120 days (ref)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Alzheimer's disease onset
Time Frame: Through study completion (a median of 144 days)
|
Time to Alzheimer's disease onset.
Please refer to uploaded protocol for full definition due to size limitations.
|
Through study completion (a median of 144 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Madhav Thambisetty, MD, PhD, National Institute on Aging (NIA)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2022
Primary Completion (Actual)
July 7, 2023
Study Completion (Actual)
December 31, 2023
Study Registration Dates
First Submitted
July 11, 2022
First Submitted That Met QC Criteria
July 11, 2022
First Posted (Actual)
July 14, 2022
Study Record Updates
Last Update Posted (Actual)
August 11, 2025
Last Update Submitted That Met QC Criteria
July 25, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Hormone Antagonists
- Respiratory System Agents
- Anti-Asthmatic Agents
- Bronchodilator Agents
- Anti-Allergic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP1A2 Inducers
- Leukotriene Antagonists
- Fluticasone
- Montelukast
Other Study ID Numbers
- 2019P003607-10
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.